Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig

Abstract

In our previous study, enrofloxacin-loaded docosanoic acid solid lipid nanoparticles (SLNs) could be effectively delivered to cells in vitro. In this study, its properties and exploitation as possible oral and intramuscular sustained release formulations for pigs were studied after being made into suspension. The re-dispersed time and sedimentation rate of the nanosuspension were 55 s and 1, respectively. It showed good stability when stored away from light and sustained release in pH = 7.4 PBS buffer. The suspension exhibited no irritation at the injection site and good palatability. Compared with commercial injection and soluble powder, the nanosuspension increased the bioavailability of enrofloxacin by 1.63 and 2.38 folds, and extended the mean residence time (MRT) of the drug from 11.27 and 12.33 to 37.76 and 35.15 h after intragastric and intramuscular administration, respectively. These results suggest that docosanoic acid SLN suspension (DAS) might be a promising oral and intramuscular sustained release formulation to enhance the pharmacological activity of enrofloxacin.

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

“…Tao et al 49 and Elbahwy et al 50 developed enrofloxacin-loaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

“…47 The lipid excipients existing in the SLN structure protect the encapsulated drug against chemical and enzymatic degradation and alter the release amount of drug. 48 Tao et al 49 and Elbahwy et al 50 developed enrofloxacinloaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

“…Tao et al 49 and Elbahwy et al 50 developed enrofloxacin-loaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

“…47 The lipid excipients existing in the SLN structure protect the encapsulated drug against chemical and enzymatic degradation and alter the release amount of drug. 48 Tao et al 49 and Elbahwy et al 50 developed enrofloxacinloaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

pH‐driven entrapment of enrofloxacin in casein‐based nanoparticles for the enhancement of oral bioavailability

“…Thus, how to enhance its solubility and improve bioavailability are key issues to be solved by developing new preparations. Various nanoparticle carriers have been developed to ameliorate the shortcomings of ENR; however, the high cost of encapsulation materials, limited availability, uncertain biocompatibility, and residual organic solvents prevent them from being used for industrial peer review (Tao et al., 2019 ). Cas is deemed as a GRAS ingredient, which not only has ideal gelling property, emulsifying property, and water binding property but also has wide applicability in drug release.…”

Research Progress in the Preparation of Enrofloxacin for Use in Veterinary Medicine

“…Eicosanoic acid as a carrier for enrofloxacin nanoparticle preparation increased bioavailability 1.63-and 2.38-fold compared with commercial injection and soluble powders, respectively. The MRT was also increased from 11.2 and 12.33 h to 37.76 and 35.15 h, respectively (Tao et al, 2019).…”

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

“…Tao et al 49 and Elbahwy et al 50 developed enrofloxacin-loaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

“…47 The lipid excipients existing in the SLN structure protect the encapsulated drug against chemical and enzymatic degradation and alter the release amount of drug. 48 Tao et al 49 and Elbahwy et al 50 developed enrofloxacinloaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

pH‐driven entrapment of enrofloxacin in casein‐based nanoparticles for the enhancement of oral bioavailability

“…Thus, how to enhance its solubility and improve bioavailability are key issues to be solved by developing new preparations. Various nanoparticle carriers have been developed to ameliorate the shortcomings of ENR; however, the high cost of encapsulation materials, limited availability, uncertain biocompatibility, and residual organic solvents prevent them from being used for industrial peer review (Tao et al., 2019 ). Cas is deemed as a GRAS ingredient, which not only has ideal gelling property, emulsifying property, and water binding property but also has wide applicability in drug release.…”

Research Progress in the Preparation of Enrofloxacin for Use in Veterinary Medicine

“…Eicosanoic acid as a carrier for enrofloxacin nanoparticle preparation increased bioavailability 1.63-and 2.38-fold compared with commercial injection and soluble powders, respectively. The MRT was also increased from 11.2 and 12.33 h to 37.76 and 35.15 h, respectively (Tao et al, 2019).…”

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

“…Tao et al 49 and Elbahwy et al 50 developed enrofloxacin-loaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

“…47 The lipid excipients existing in the SLN structure protect the encapsulated drug against chemical and enzymatic degradation and alter the release amount of drug. 48 Tao et al 49 and Elbahwy et al 50 developed enrofloxacinloaded docosanoic acid SLNs and glibenclamide-SLNs, respectively. The formulations showed different plasma concentration time curves, sustained release profiles, and better pharmacokinetic parameters in blood circulation when compared to solution form.…”

pH‐driven entrapment of enrofloxacin in casein‐based nanoparticles for the enhancement of oral bioavailability

“…Thus, how to enhance its solubility and improve bioavailability are key issues to be solved by developing new preparations. Various nanoparticle carriers have been developed to ameliorate the shortcomings of ENR; however, the high cost of encapsulation materials, limited availability, uncertain biocompatibility, and residual organic solvents prevent them from being used for industrial peer review (Tao et al., 2019 ). Cas is deemed as a GRAS ingredient, which not only has ideal gelling property, emulsifying property, and water binding property but also has wide applicability in drug release.…”

Research Progress in the Preparation of Enrofloxacin for Use in Veterinary Medicine

“…Eicosanoic acid as a carrier for enrofloxacin nanoparticle preparation increased bioavailability 1.63-and 2.38-fold compared with commercial injection and soluble powders, respectively. The MRT was also increased from 11.2 and 12.33 h to 37.76 and 35.15 h, respectively (Tao et al, 2019).…”